275 related articles for article (PubMed ID: 31792431)
1. Financial toxicity associated with treatment of localized prostate cancer.
Imber BS; Varghese M; Ehdaie B; Gorovets D
Nat Rev Urol; 2020 Jan; 17(1):28-40. PubMed ID: 31792431
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer.
Stone BV; Laviana AA; Luckenbaugh AN; Huang LC; Zhao Z; Koyama T; Conwill R; Hoffman K; Joyce DD; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Barocas DA
J Urol; 2021 Mar; 205(3):761-768. PubMed ID: 33252300
[TBL] [Abstract][Full Text] [Related]
3. Out-of-pocket costs for commercially insured patients with localized prostate cancer.
Wallis CJD; Joyce DD; Klaassen Z; Luckenbaugh AN; Laviana AA; Penson D; Dusetzina SB; Barocas DA
Urol Oncol; 2021 Dec; 39(12):797-805. PubMed ID: 34600803
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of illness associated with localized prostate cancer in the United States.
Gustavsen G; Gullet L; Cole D; Lewine N; Bishoff JT
Future Oncol; 2020 Jan; 16(1):4265-4277. PubMed ID: 31802704
[No Abstract] [Full Text] [Related]
5. Predictors of Financial Toxicity Among United States Prostate Cancer Survivors: Results From a National Survey.
Stone BV; Labban M; Filipas DK; Beatrici E; Frego N; Qian ZJ; Voleti SS; Lipsitz SR; Kibel AS; Trinh QD; Cole AP
Urol Pract; 2023 Sep; 10(5):459-466. PubMed ID: 37498685
[TBL] [Abstract][Full Text] [Related]
6. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
Reinhold T; Dornquast C; Börgermann C; Weißbach L
Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Cost of Illness of Prostate Cancer in Iran.
Mojahedian MM; Toroski M; Keshavarz K; Aghili M; Zeyghami S; Nikfar S
Clin Ther; 2019 Jan; 41(1):50-58. PubMed ID: 30545740
[TBL] [Abstract][Full Text] [Related]
8. Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country.
Ting CY; Teh GC; Yu KL; Alias H; Tan HM; Wong LP
Support Care Cancer; 2020 Apr; 28(4):1703-1715. PubMed ID: 31292755
[TBL] [Abstract][Full Text] [Related]
9. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
[TBL] [Abstract][Full Text] [Related]
10. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.
Sennfält K; Carlsson P; Thorfinn J; Frisk J; Henriksson M; Varenhorst E
Scand J Urol Nephrol; 2003; 37(3):226-31. PubMed ID: 12775282
[TBL] [Abstract][Full Text] [Related]
11. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
12. Financial toxicity and strain among men receiving prostate cancer care in an equal access healthcare system.
Bauer AG; Jefferson M; Nahhas GJ; Savage S; Drake R; Lilly M; Ambrose L; Caulder S; Mahvi D; Hughes Halbert C
Cancer Med; 2020 Dec; 9(23):8765-8771. PubMed ID: 33070458
[TBL] [Abstract][Full Text] [Related]
13. Quality of life and economic considerations in the management of prostate cancer.
Turini M; Redaelli A; Gramegna P; Radice D
Pharmacoeconomics; 2003; 21(8):527-41. PubMed ID: 12751912
[TBL] [Abstract][Full Text] [Related]
14. Financial toxicity: a potential side effect of prostate cancer treatment among Australian men.
Gordon LG; Walker SM; Mervin MC; Lowe A; Smith DP; Gardiner RA; Chambers SK
Eur J Cancer Care (Engl); 2017 Jan; 26(1):. PubMed ID: 26423576
[TBL] [Abstract][Full Text] [Related]
15. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
16. The Association Between Financial Toxicity and Treatment Regret in Men With Localized Prostate Cancer.
Joyce DD; Wallis CJD; Huang LC; Hoffman KE; Zhao Z; Koyama T; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Barocas DA
JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36255249
[TBL] [Abstract][Full Text] [Related]
17. Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies.
Lentz R; Benson AB; Kircher S
J Surg Oncol; 2019 Jul; 120(1):85-92. PubMed ID: 30650186
[TBL] [Abstract][Full Text] [Related]
18. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
Wood R; Taylor-Stokes G
BMC Cancer; 2019 Mar; 19(1):214. PubMed ID: 30849964
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
Govers TM; Caba L; Resnick MJ
J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
[TBL] [Abstract][Full Text] [Related]
20. The association of financial difficulties and out-of-pocket payments with health-related quality of life among breast, prostate and colorectal cancer patients.
Koskinen JP; Färkkilä N; Sintonen H; Saarto T; Taari K; Roine RP
Acta Oncol; 2019 Jul; 58(7):1062-1068. PubMed ID: 30943813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
